Expert Ratings for Biogen
Portfolio Pulse from Benzinga Insights
In the last quarter, Biogen (NASDAQ:BIIB) received 3 bullish, 4 somewhat bullish, and 2 indifferent ratings from analysts. The company's average 12-month price target is $329.89, a decrease of 0.34% from the previous average of $331.00.
November 09, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen received mostly positive ratings from analysts in the last quarter. The average 12-month price target has slightly decreased.
The majority of the ratings Biogen received in the last quarter were bullish or somewhat bullish, indicating a generally positive outlook. However, the slight decrease in the average 12-month price target could suggest some uncertainty about the company's future performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100